XBIO
Xenetic Biosciences, Inc.
stockNASDAQ
xenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. xenetic is also working together with shire plc (formerly baxalta, baxter incorporated and baxter healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation factor viii. this collaboration relies on xenetic's polyxen technology to conjugate polysialic acid
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.82 | 2026-10-27 | +10.71% | 7.749 |
| 1M | 2.24 | 2026-10-02 | -9.82% | 2.291 |
| 3M | 2.66 | 2026-08-03 | -24.06% | 3.578 |
| 6M | 2.96 | 2026-05-04 | -31.76% | 2.122 |
| 1Y | 3.12 | 2025-11-03 | -35.26% | 1.570 |
| 2Y | 3.66 | 2024-11-04 | -44.85% | — |
| 5Y | 18.30 | 2021-11-03 | -88.96% | 0.262 |
Xenetic Biosciences, Inc. (NASDAQ:XBIO) stock price today is $2.02, and today's volume is 7,606. XBIO is down 1.942% today. The 30 day average volume is 35,002. XBIO market cap is $4.73M with 2.34M shares outstanding.